Ndi-5001

Phase 1

Otsuka

Ndi-5001 is one of 5 therapeutic programs targeting Diabetes Insipidus. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Diabetes InsipidusRecruiting

Diabetes InsipidusPhase 1

Recruiting

Competition

Competitive Landscape

5 competitors in Diabetes Insipidus

#DrugCompanyPhaseTrials

Pitressin

AAultman Health Foundation

Approved

—2

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Glucophage

Pitocin

Ndi-5001

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1Recruiting

Diabetes Insipidus

NCT07525960

Clinical

Trials by Indication[1]

Diabetes Insipidus1 trial

A Phase 1b, Open-label Trial to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of NDI-5001 in a Capsule Following Daily Oral Doses to Adult Males With X-linked Congenital Nephrogenic Diabetes Insipidus

Recruiting· Otsuka logo

Otsuka·Phase 1·NCT07525960·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Ndi-5001. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Ndi-5001. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Otsuka company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: Otsuka

Ndi-5001

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Diabetes Insipidus1 trial

References

Drug Info

Quick Facts

Related News